Evolution of the Average Target: Ironwood Pharmaceuticals, Inc.

Evolution of the Target Price: Ironwood Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Ironwood Pharmaceuticals, Inc.

68faed35d.CGTBaClNze9fxkt5KC8S5Yumshzz9IHstK8Atn1ELMg.OS6eWREeid83gQwzWGphh7jlxmvKk7Sj-t1I5ioTbY5RVJAAGgqBnQyTew~85f152462c83d0973c8be578462cef58
11-05 AbbVie, Ironwood Win FDA Approval for Linzess to Treat Children With Irritable Bowel Syndrome With Constipation MT
25-08-07 Ironwood Pharmaceuticals Q2 revenue beats expectations RE
25-04-15 Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 MT
25-04-15 Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 MT
24-09-09 Leerink Partners Initiates Coverage on Ironwood Pharmaceuticals With Market Perform Rating, $5 Price Target MT
24-02-16 Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating MT
24-01-17 Craig-Hallum Starts Coverage on Ironwood Pharmaceuticals with Buy Rating, $21 Price Target MT
23-09-28 JMP Securities Starts Ironwood Pharmaceuticals at Market Outperform, $22 Price Target MT
23-05-23 Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating MT
22-09-02 Capital One Securities Initiates IRWD at Overweight with $15 Price Target MT
22-08-16 Wells Fargo Adjusts Ironwood Pharmaceuticals' Price Target to $13 from $12, Maintains Equalweight Rating MT
22-04-22 Piper Sandler Starts Ironwood Pharmaceuticals at Overweight With $16 Price Target MT
21-10-12 Ironwood Pharmaceuticals : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $14 From $13, Maintains Equal-Weight Rating MT
21-07-16 Ironwood Pharmaceuticals : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $12 From $11, Maintains Equal-Weight Rating MT
20-11-06 Ironwood Pharmaceuticals : Morgan Stanley Adjusts Ironwood Pharmaceuticals' Price Target to $12 from $11, Keeps Equalweight Rating MT
20-11-06 Ironwood Pharmaceuticals : Credit Suisse Adjusts Ironwood Pharmaceuticals' Price Target to $12 From $11, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+6.28%
+17.32%
-7.13%
+4.12%
+64.15%
+47.58%
- - -11.87%
+48.29%
Average +21.09%
Weighted average by Cap. +8.59%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.080USD
Average target price
6.100USD
Spread / Average Target
+49.51%
High Price Target
10.00USD
Spread / Highest target
+145.10%
Low Price Target
3.700USD
Spread / Lowest Target
-9.31%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. IRWD Stock
  4. I76 Stock
  5. Consensus Ironwood Pharmaceuticals, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!